However, on univariate analysis we found an OS benefit in patients whose tumors expressed both tumor PD-L1 ≥ 5% and CD8 high (score 3 or 4) [HR=0.62 (95% CI 0.41-0.93), p=0.021]. Here, CD8A is linked to neoplasm.